Novo Nordisk Raises FY26 Free Cash Flow Outlook To DKK 60B-70B From DKK 45B-55B; Lowers Capex Outlook To About DKK 50B From DKK 55B
Share
Why It Matters
Novo Nordisk expects to have more cash left over next year. They also plan to spend less money on buildings and equipment.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.